PCA
VTGN icon

Personal Capital Advisors’s VistaGen Therapeutics VTGN Stock Holding History

Personal Capital Advisors’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$2.79K Buy
+903
New +$3.4K ﹤0.01% 489

Other funds holding VTGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Personal Capital Advisors's VTGN Position: Q4 2022 in Review

Personal Capital Advisors opened a new position in VistaGen Therapeutics (VTGN) in Q4 2022: 903 shares worth $2.79K. The stake represents ﹤0.01% of the portfolio and ranks #489 among its holdings.

85 funds tracked by Wall St. Rank hold VTGN as of Q4 2022.

  • Personal Capital Advisors held 903 shares of VistaGen Therapeutics worth $2.79K as of Q4 2022.
  • VistaGen Therapeutics was a new Personal Capital Advisors position in Q4 2022.
  • VistaGen Therapeutics made up ﹤0.01% of Personal Capital Advisors's portfolio in Q4 2022, its #489 holding.
  • 85 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q4 2022.

Based on Personal Capital Advisors's 13F filing for Q4 2022, filed 15 Feb 2023.